Genprex, Inc.

NasdaqCM:GNPX Voorraadrapport

Marktkapitalisatie: US$7.7m

Genprex Dividend

Dividend criteriumcontroles 0/6

Genprex does not have a record of paying a dividend.

Belangrijke informatie

n/a

Dividendrendement

-172.2%

Terugkoop Rendement

Totaal aandeelhoudersrendement-172.2%
Toekomstig dividendrendementn/a
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente dividendupdates

Geen updates

Recent updates

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Aug 16
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Jan 31
Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Oct 12
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14
We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27
We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Insufficient data to determine if GNPX's dividends per share have been stable in the past.

Groeiend dividend: Insufficient data to determine if GNPX's dividend payments have been increasing.


Dividendrendement versus markt

Genprex Dividendrendement versus markt
Hoe verhoudt GNPX dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (GNPX)n/a
Markt onderkant 25% (US)1.5%
Markt Top 25% (US)4.5%
Gemiddelde industrie (Biotechs)2.2%
Analist prognose (GNPX) (tot 3 jaar)n/a

Opmerkelijk dividend: Unable to evaluate GNPX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hoog dividend: Unable to evaluate GNPX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Winstuitkering aan aandeelhouders

Verdiendekking: Insufficient data to calculate GNPX's payout ratio to determine if its dividend payments are covered by earnings.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Unable to calculate sustainability of dividends as GNPX has not reported any payouts.


Ontdek bedrijven met een sterk dividend